ARTHQ (Arch Therapeutics) Current Accrued Expense: $1.65 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Current Accrued Expense?

Arch Therapeutics ARTHQ -99.00% 12 Current Accrued Expense is $1.65 Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Arch Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2024 was $1.65 Mil.

Arch Therapeutics's quarterly Current Accrued Expense increased from Dec. 2023 ($1.34 Mil) to Mar. 2024 ($1.39 Mil) and increased from Mar. 2024 ($1.39 Mil) to Jun. 2024 ($1.65 Mil).

Arch Therapeutics's annual Current Accrued Expense increased from Sep. 2021 ($0.32 Mil) to Sep. 2022 ($0.45 Mil) and increased from Sep. 2022 ($0.45 Mil) to Sep. 2023 ($1.29 Mil).

Arch Therapeutics Current Accrued Expense Related Terms

Arch Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Current Accrued Expense Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.25 0.32 0.45 1.29

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.97 1.29 1.34 1.39 1.65
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.65 Mil mean?
Arch Therapeutics (ARTHQ) has a Current Accrued Expense of $1.65 Mil as of Jun. 2024. Current Accrued Expense records the total amount of accrued expenses. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' Current Accrued Expense too high?
Arch Therapeutics' current Current Accrued Expense is $1.65 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Current Accrued Expense compare to GRTSQ and MTEM?
Arch Therapeutics' Current Accrued Expense of $1.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Arch Therapeutics and its competitors. Arch Therapeutics's current Current Accrued Expense is $1.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Current Accrued Expense of $1.65 Mil. The current Current Accrued Expense is $1.65 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Current Accrued Expense is $1.65 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price